EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS(®) system



Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS(®) system



Journal of Clinical Virology 78(): 20-26



Detection of antibodies (anti-HCV) against hepatitis C virus (HCV) is indispensable for screening and diagnosis of viral hepatitis and for the viral safety of blood, tissue or organ donations. It gains additional importance by the new HCV drugs which improve the therapeutic possibilities dramatically. To evaluate the performance of a newly developed immune assay for anti-HCV based on the well-established VIDAS platform. The assay was evaluated with samples from anti-HCV negative blood donors and from patients with or without HCV markers in six centres in France, Spain and Egypt. The status of the samples was determined by using CE-marked immune assays (Architect, AxSym, Prism, Vitros), two immunoblots (RIBA, Inno-Lia) and/or HCV RNA results. Specificity was 99.67% in 10,320 French blood donors without anti-HCV, 99.5% in 200 anti-HCV negative hospitalized European patients and 99.0% in 198 negative patients from Egypt. Sensitivity was 99.7% in 1054 patients pretested positive by other assays; 345 patients with known genotype had genotype 1-6; 61 patients were co-infected with HIV. VIDAS was reactive in 78% of 91 patients with uncertain or very weak anti-HCV. It became on average positive at day 37 with seroconversion panels. This multicentric, international study with >12,000 samples show that the new VIDAS anti-HCV assay is very suitable for screening and confirmation of HCV infection. Sensitivity, specificity and recognition of seroconversion compare favorably with well-established CE-marked tests and help to clarify discrepant results obtained with other assays.

(PDF emailed within 0-6 h: $19.90)

Accession: 058355896

Download citation: RISBibTeXText

PMID: 26962723

DOI: 10.1016/j.jcv.2016.03.001



Related references

Analytical and clinical evaluation of vidas hbcm a quantitative test for the detection of hepatitis b core ag hbc igm antibodies on the biomerieux vidas automated system. Clinical Chemistry 38(6): 1082, 1992

Preliminary evaluation of the vitek immunodiagnostic assay system vidas for detection of antibodies to human immunodeficiency virus hiv. Abstracts of the Annual Meeting of the American Society for Microbiology 89: 401, 1989

Evaluation of the vitek immunodiagnostic assay system vidas for the detection of igg antibodies to toxoplasma gondii in clinical specimens. Abstracts of the General Meeting of the American Society for Microbiology 91: 397, 1991

Evaluation of the VIDAS Anti-HCV Assay for Detection of Hepatitis C Virus Infection. Annals of Laboratory Medicine 36(6): 550-554, 2016

Evaluation of the automated vitek immunodiagnostic assay system (VIDAS) for the detection of measles (rubeola) IgG antibodies. Clinical and Diagnostic Virology 3(3): 207-213, 1995

Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. Journal of Clinical Microbiology 36(4): 862-865, 1998

Evaluation of performance of the RIBA processor system for automated analysis of the strip immunoblot assay for detection of antibodies to hepatitis C virus. Journal of Clinical Microbiology 35(9): 2331-2336, 1997

Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. Journal of Clinical Microbiology 41(2): 651-656, 2003

Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. Journal Of Medical Virology. 43(3): 259-261, 1994

Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. Journal of Pediatric Gastroenterology and Nutrition 16(4): 458-464, 1993

Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV. Journal of Virological Methods 127(2): 165-167, 2005

Multicenter evaluation of a fully automated screening test, VIDAS HIV 1+2, for antibodies to human immunodeficiency virus type 1 and 2. Journal of Clinical Microbiology 32(10): 2559-2563, 1994

Development of a sensitive and fully automated assay for the quantitative determination of total antibodies against Hepatitis A virus for the Vidas instruments. Abstracts of the General Meeting of the American Society for Microbiology 97(0): 582, 1997